Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Nov 2024 Status changed from completed to discontinued.
- 24 Aug 2022 Status changed from active, no longer recruiting to completed.
- 15 May 2022 Planned End Date changed from 10 Jun 2022 to 9 Jun 2022.